trending Market Intelligence /marketintelligence/en/news-insights/trending/Buc9he6C3c-HEDM45SuaQA2 content esgSubNav
In This List

Ziopharm Oncology names president

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Ziopharm Oncology names president

ZIOPHARM Oncology Inc. said David Mauney has been promoted to president, effective Dec. 13.

Mauney joined the company in 2017 as executive vice president and chief business officer. Previously, Mauney served as managing director at Harvest Capital Strategies LLC.

Boston-based Ziopharm Oncology is a biotechnology company that focuses on acquiring, developing and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens.